Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer

Acta Radiologica

Volumn 49, Issue 9, 2008, Pages 991-994

  Chen, C M ^b   Chang, J W C ^b   Cheung, Y C ^a   Lin, G ^b   Hsieh, J J ^b   Hsu, T ^b   Huang, S F ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

Computed tomography; EGFR mutation; Lung biopsy; Lung cancer

Indexed keywords

BIOACTIVITY; BIOLOGICAL ORGANS; CELL GROWTH; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC RADIOGRAPHY; ELECTRIC INSTRUMENT TRANSFORMERS; MEDICAL IMAGING; NEEDLES; PEPTIDES; TOMOGRAPHY;

CLINICAL RESPONSES; COMPUTED TOMOGRAPHIES; COMPUTED TOMOGRAPHY; EGFR MUTATION; EPIDERMAL GROWTH FACTOR RECEPTORS; GEFITINIB; GENE MUTATIONS; LUNG BIOPSY; LUNG CANCER; LUNG CANCERS; LUNG TUMORS; MUTATION ANALYSIS; NEEDLE BIOPSIES; NEW CLASSES; RESPONSE RATES;

BIOPSY;

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG ANTAGONISM; FEMALE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METHODOLOGY; MIDDLE AGED; MUTATION; NEEDLE BIOPSY; PATHOLOGY; PROTO ONCOGENE;

ADULT; AGED; BIOPSY, NEEDLE; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 54349083304     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1080/02841850802294410     Document Type: Article

References (18)

1. Spiro SG, Porter JC. Lung cancer - where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 2002; 166:1166-96.
2. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest 2006; 130: 1211-9.
3. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22: 330-53.
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandier A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
6. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
7. Borczuk AC, Shah L, Pearson GD, Walter KL, Wang L, Austin JH, et al. Molecular signatures in biopsy specimens of lung cancer. Am J Respir Crit Care Med 2004;170:167-74.
8. Fnjita S, Mio T, Sonobe M, Kamiyama K, Masago K, Miyahara R, et al. Accuracy of epidermal growth factor receptor mutation analysis on the basis of small biopsy specimens in patients with nonsmall cell lung cancer. Int J Cancer 2006; 119:1751-2.
9. Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 2006;97:642-8.
10. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006;12:3915-21.
11. Shih JY, Gow CH, Yu CJ, Yang CH, Chang YL, Tsai MF, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006:118:963-9.
12. Montaudon M, Latrabe V, Pariente A, Corneloup O, Begueret H, Laurent F. Factors influencing accuracy of CT-guided percutaneous biopsies of pulmonary lesions. Eur Radiol 2004;14:1234-40.
13. Meert AP, Martin B, Verdebout JM, Paesmans M, Berghmans T, Ninane V, et al. Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer 2004; 44:295-301.
14. Mu XL, Li LY, Zhang XT, Wang MZ, Feng RE, Cui QC, et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin Cancer Res 2005; 11:4289-94.
15. Zhang XT, Li LY, Mu XL, Cui QC, Chang XY, Song W, et al. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol 2005;16:1334-42.
16. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004; 10:8195-203.
17. Hsieh MH, Fang YF, Chang WC, Kuo HP, Lin SY, Liu HP, et al. Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer 2006;53:311-22.
18. Chou TY, Chiu CH, Li LH, Hsiao C, Tzen CY, Chang KT, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005;11: 3750-7.